Ohio State Navbar

News


Immunology Seminar Program


August 07, 2015

On Tuesday, November 17th 12-4pm, 400 Prior Hall, Jianhua Yu, PhD, Associate Professor, Division of Hematology, Department of Internal Medicine at Ohio State, and member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC - James, will present "Understanding NK Cell Biology and Driving and Mobilizing Immune Cells to Kill Tumor Cells" The rest of the story



Clara D. Bloomfield, MD, FASCO: Never One to Back Down From a Challenge


August 07, 2015

Clara D. Bloomfield, MD, a Distinguished University Professor at Ohio State who also serves as cancer scholar and senior adviser to the OSUCCC – James, is featured in the July 10 edition of The ASCO Post in a story titled “Clara D. Bloomfield, MD, FASCO: Never One to Back Down From a Challenge.” To read this story, click here The rest of the story



Large NCI Grants Will Aid OSU Research In Lung Cancer & CLL


August 07, 2015

The other study, led by PIs Jennifer Woyach, MD, assistant professor in the Division of Hematology at Ohio State, and member of the Leukemia Research Program at the OSUCCC – James, and Amy Johnson, PhD, associate professor in the Division of Hematology at Ohio State, and member of the Leukemia Research Program at the OSUCCC – James, will focus on improving BTK-directed therapy for patients with CLL. Read more The rest of the story



Congratulations Dr. Byrd


July 24, 2015

The American Society of Hematology will present the 2015 William Dameshek Prize to John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) for his contributions to the development of transformative treatments for chronic lymphocytic leukemia (CLL), most notably rituximab and ibrutinib. The rest of the story



Study Discovers Negative Regulator of Natural Killer Cell Maturation


June 05, 2015

STUDY DISCOVERS NEGATIVE REGULATOR OF NATURAL KILLER CELL MATURATION A study led by researchers at the OSUCCC – James has identified a regulatory pathway in natural killer (NK) cells that inhibits their maturation and homing behavior. NK cells are one of the body’s first lines of defense against viruses and cancer. The findings, published in the journal Immunity, could lead to strategies for boosting natural killer cell activity against cancer and viral infections. Jianhua Yu, PhD, a member of the Leukemia Research Program at the OSUCCC – James, was principal investigator. Read more: The rest of the story



Byrd Wins National Award for Innovative Clinical Research


June 05, 2015

BYRD WINS NATIONAL AWARD FOR INNOVATIVE CLINICAL RESEARCH John C. Byrd, MD, co-leader of the Leukemia Research Program at the OSUCCC – James, received the 2015 Charles G. Moertel Lecture Award from the Alliance for Clinical Trials in Oncology at the Alliance Spring Group Meeting held May 13-16 in Chicago. The Alliance presents the award annually to an investigator whose research within the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) results in a major impact on community cancer practice. Read more: The rest of the story



Bloomfield Honored as a ‘Giant of Cancer Care'


June 05, 2015

Clara D. Bloomfield, MD, a Distinguished University Professor who serves as cancer scholar and senior adviser to the OSUCCC – James, was honored as one of 12 winners in the 2015 Giants of Cancer Care awards program sponsored by OncLive, a Web resource for physicians and other health professionals who focus on treating cancer. Read more: The rest of the story



James S. Blachly, MD, One of six receipients of a Young Investigator Award


May 05, 2015

James S. Blachly, MD, assistant professor in the Division of Hematology at Ohio State and member of the Leukemia Research Program at the OSUCCC – James, is one of six recipients of a Young Investigator Award from the National Comprehensive Cancer Network (NCCN) Foundation®. His grant is for $150,000 over two years for a project titled “Genomic Stratification and Prognostication of Adult Acute Myeloid Leukemia by Combination Mutation Status.” Blachly’s co-mentors for the award are Clara D. Bloomfield, MD, a Distinguished University Professor who also serves as OSU cancer scholar and senior adviser to the OSUCCC – James, and John C. Byrd, MD, director of the Division of Hematology and co-leader of the Leukemia Research Program. The rest of the story



OSU Researchers Contribute to ASCO's Choice for 'Cancer Advance of the Year'


March 31, 2015

OSU Researchers Contribute to ASCO’s Choice for ‘Cancer Advance of the Year’ Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) scientists played a key role in some of the recent research that has helped transform treatment for chronic lymphocytic leukemia (CLL)—a transformation that the American Society of Clinical Oncology (ASCO) calls the “Cancer Advance of the Year.” ASCO’s Clinical Cancer Advances 2015 notes that four new therapies, including two targeted drugs and two immunotherapies, have been approved by the FDA in just a year’s time for CLL, the most common form of adult leukemia. Much of the research leading to approval of the drug ibrutinib, one of the two targeted agents, was performed by scientists at the OSUCCC – James. The rest of the story



Researchers Detail Reasons for Ibrutinib Therapy Discontinuation in CLL


March 31, 2015

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study at the OSUCCC – James that was published in JAMA Oncology. Kami Maddocks,MD, of the Division of Hematology at Ohio State, was first author on the study, and Jennifer Woyach, MD, also of the Division of Hematology and a member of the Leukemia Research Program at the OSUCCC – James, was senior author. The rest of the story



Next